The biomarkers are biological molecules finding in the blood; and other body fluids that could signal a normal or abnormal process; including the presence of a disease. By this cell deriving extracellular vesicles; can be using as a biomarker reservoir for glioblastoma tumor subtyping. But cancer biomarkers provide a signal of the presence of cancer cells; which are considering biological signatures of disease.
But the researchers report that specific biomarkers; linking to extracellular vesicles, which are tiny packages released by cells into body fluids so they can communicate with each other. Extracellular vesicles (EVs) is a way through which tumor cells; which include cancer stem cells, self-regulate, and communicate with their stromal counterparts. This way, they maintain such high-tumoral heterogeneity.
Biomarkers are biological molecule
All brain cancers are complex, but glioblastoma is very aggressive because of how fast it kills its victims. Usually, patients with this type of brain tumor die within just months. The tumor stems from the brain or spinal cord, and the symptoms include weakness, fatigue, lack of coordination, vomiting, nausea, blurred vision, headaches, and seizures.
Glioblastoma multiforme (GBM), otherwise called glioblastoma, is a fast-growing and aggressive glioma that forms from the glial cells, which helps support nerve cell health. The tumor is very aggressive that it grows rapidly, usually spreading into nearby brain tissue. The disease is very devastating, often resulting in death in the first 15 months after being diagnosing.
Nerve cell health
In the United States, about 22,850 adults were diagnosing with brain and other types of cancer affecting the nervous system in 2015. At present, many studies are focusing on looking into the possibility of developing liquid-biopsies; such as blood tests to spot not only brain cancer but also other types of cancer, like pancreatic.
Instead of getting a sample of tissue from the affected area; liquid biopsies would let doctors get a blood sample and detect biomarkers to diagnose the presence of tumors. Liquid biopsies mean a less invasive procedure for patients; and arguably quicker results something which is invaluable for those with an aggressive tumor that severely cuts life expectancy. But it could also mean better patient follow-up care, as a simple test can be carried out to check for the efficacy of existing treatments or monitoring relapse. The more we know about biomarkers, the better; so this is a step which should provide hope for anyone whose lives have been impacted by glioblastoma